Randomized Parallel Group Study Comparing the Renal Safety of CAPTISOL-Enabled™ Iohexol (CE-Iohexol) Injection and Omnipaque™ (Iohexol) Injection in Patients With Impaired Renal Function Undergoing Coronary Angiography
Latest Information Update: 14 Apr 2022
At a glance
- Drugs Iohexol (Primary)
- Indications Acute kidney injury
- Focus Diagnostic use
- Sponsors Ligand Pharmaceuticals
- 01 Apr 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 26 Jun 2021 Planned End Date changed from 1 Jul 2022 to 1 Apr 2023.
- 26 Jun 2021 Planned primary completion date changed from 1 Jun 2022 to 1 Mar 2023.